Ketamine Increases Brain PDE4 Binding in Rats and Monkeys

Major depressive disorder affects more than 300 million people globally, yet many patients fail to achieve remission with standard monoaminergic medications that target traditional neurotransmitter pathways [1]. Intravenous racemic ketamine has emerged as a rapid acting intervention for treatment resistant cases, with meta analyses of randomized controlled trials showing it is more effective than theta burst stimulation (a non invasive neuromodulation technique) within the first week of administration [2]. In these difficult to treat populations, ketamine and its intranasal enantiomer, esketamine, have demonstrated the ability to reduce functional impairment and improve patient reported quality of life [3, 4]. However, the clinical utility of this N methyl D aspartate (NMDA) receptor antagonist is often limited by transient adverse events, including dissociation (a sense of detachment from one’s environment) and acute blood pressure elevations [5]. A new study now offers fresh insights into the underlying molecular mechanisms that may explain these rapid clinical improvements.